The Biggest Discussions in Retina from the 2022 ASRS Annual Meeting
This episode of DocTalk features 5 expert retina specialists discussing the top line data from the conference.
Arshad Khanani, MD: Durability of Faricimab for nAMD Based on Two-Year Data
Over 60% of patients in the second year of TENAYA and LUCERNE were on 16 week dosing in the faricimab group.
Yasha Modi, MD: Machine Learning Helps Predict Visual Outcomes, Treatment Patterns
Machine learning algorithms successfully predicted visual and anatomic outcomes and dosing frequency in patients with macular edema secondary to CRVO.
Theodore Leng, MD: Anti-VEGF Utilization Patterns in Patients with DME
Data show 77% of eyes with DME in the IRIS Registry received only one type of anti-VEGF agent over an average follow-up of 2.3 years.
Aleksandra Rachitskaya, MD: The Promise of PDS Despite Retinal Fluid Presence
The port delivery system provides good visual outcomes for patients with nAMD despite presence of fluid in post-hoc analysis of Archway trial.
David Lally, MD: Avacincaptad Pegol Shows Reduction of GA Lesion Growth
A post-hoc analysis of the GATHER1 trial suggests avacincaptad pegol reduced GA lesion growth across all distances from the foveal center point, when compared to sham.
Dilsher Dhoot, MD: Effect of Time to Aflibercept Injection on CRVO Outcomes
Longer time to intravitreal aflibercept injection (>3 months) showed less visual improvement versus shorter time (<1 month).
Rishi Singh, MD: Durability of EYP-1901 for Maintenance of nAMD
Dr. Singh discusses the promise of durability with the agent and the potential for reducing the amount of patient visits, while preserving visual outcomes.
Two-Year Data Reinforces Improved Vision Outcomes with Faricimab in Wet AMD
More than 60% of faricimab patients could be treated every 4 months at 2-year mark of TENAYA and LUCERNE studies.
Veeral Sheth, MD: Insights Into CST Fluctuations, Vision Outcomes with PDS Treatment
Overall 70% of the patients in both PDS with ranibizumab and ranibizumab alone had almost no retinal thickness fluctuations.
Faricimab Shows Efficacy in Treatment-Naive, Difficult-to-Treat Patients with nAMD
Real-world patients showed improvement in visual acuity and anatomic parameters, but are still at an early time point in TRUCKEE study.
Pegcetacoplan Shifts Distribution Across Lesion Growth Quartiles In GA Treatment
Evidence of pegcetacoplan treatment effect observed in the distribution of patients across quartiles in both OAKS and DERBY.
Intravitreal Pegcetacoplan Well-Tolerated in Patients with Geographic Atrophy
Monthly or every other month intravitreal pegcetacoplan reported to be tolerated in DERBY and OAKS trials.
Ellipsoid Zone Integrity a Key Factor for VA in Eyes with nAMD Without Fluid
The best overall outcomes were attained in eyes without fluid and ellipsoid zone integrity preservation, investigators said.
Monotherapy Aflibercept Does Not Differ to Initial Bevacizumab for DME Care
An assessment of anti-VEGF dose regimen strategies concludes with little difference in outcomes among treatment arms at 2 years.
Pursuing Tailored Care for Diabetic Macular Edema
The retina field is equipped with ideal therapy and research informing implementation. Now it needs greater patient buy-in.
Intravitreal Injections Linked to Psychosocial Burden in Retina Disease Patients
Assessment from a patient survey showed an association between increased rates of injection treatment and increased restriction on usual activity for patients.
Factors Influencing Treatment of Diabetic Macular Edema
Rishi P. Singh, MD, discusses new VISTA/VIVID data showing what really influences a patients' likelihood and time to DME resolution when treated with aflibercept.
Long-Term nAMD Patient Buy-In Is Still Lacking for Anti-VEGF Therapy
Theodore Leng, MD, MS, defines the trends of patient discontinuation, and how direct caregivers may help to reduce risk of losing patients.
How Virtual Visits, Port Delivery System Therapy Can Benefit Retina Practices
Arshad Khanani, MD, MA, explains how new measures made available to ophthalmology will help address a quickly growing patient population.
Assuring Optimal Implant Insertion of Port Delivery Systems for Anti-VEGF
Veeral S. Sheth, MD, MBA, discusses what ophthalmologists will need to learn about PDS application for patients with AMD.
Anti-VEGF Continuation Wanes After 3-6 Years for Patients with nAMD
Theodore Leng, MD, MS, discusses new findings based on IRIS registry data showing long-term discontinuation trends in patients.
Arshad Khanani, MD, MA: Applying Ranibizumab PDS in Practice
An approval may be pending for the unique delivery system. An expert explains its benefit for nAMD patients and physicians alike.
Hybrid Ophthalmology Telemedicine Could Exist Beyond COVID-19
A retina care team highlighted positive patient feedback from their makeshift system; could it be a long-term solution?
COVID-19 Delays in Retina Care Are Driving Worse Vision Outcomes
A greater rate of intravitreal injection appointments were delayed last year, causing worse patient scores in BCVA and OTC.
COVID-19 Masking Did Not Influence Bacteria Eye Infections from Anti-VEGF Injections
New cohort analyses show endophthalmitis was not significantly reduced in treatment encounters where both physicians and patients were masked.
Varied Faricimab Dosing Regimens Non-Inferior to Aflibercept in Patients with DME
Findings from YOSEMITE and RHINE show a significant rate of patients on faricimab were able to extend their dosing to once every 16 weeks after a year of therapy.
Investigative Oral Retina Drug APX3330 Shows Favorable Safety, Tolerability
Positive phase 1 and 2 findings support an ongoing efficacy assessment of the Ref-1 inhibitor for diabetic retinopathy and diabetic macular edema.
Diabetic Macular Edema Trials Lack Accurate Patient Racial Representation
A new cross-sectional analysis from ASRS 2021 show White patients are generally overrepresented in randomized, controlled trials for DME.
Ranibizumab PDS, Faricimab, Gene Therapy and Top ASRS 2021 Headlines
Josh Mali, MD, of The Eyes Associates, joins HCPLive to review the key news and developments coming out of the American Society of Retina Specialists 2021 Scientific Meeting.
2 Clarke Drive Cranbury, NJ 08512